

APLASTIC ANEMIA: bone marrow transplantation

Andrea Bacigalupo

*Universita' Cattolica- Policlinico Gemelli
Rome , Italy*




Acquired SAA

HLA = Sib

≤ 40 yy

Sib BMT






EVENT FREE SURVIVAL

Age <20 , VSAA /SAA


Event IS : death or BMT

BMT: death or ext-cGvHD

1976 - 1998



1999 - 2009



**# SAA <20 with an identical sibling , BMT
first line**

CY 200 +ATG is standard of care

First line HLA identical sibling BMT for SAA; (EBMT 2001-2010)




Fig.3

SAA <20 with an identical sibling , BMT first line

**# SAA 21-40 : id SIB BMT first line;
conditioning to be optimized
(CY 200 +ATG / FCC / FCA)**





Fig.2



SAA
HLA id sibs ; 2001-2010





Fig.3

**SAA HLA id siblings; 2001-2010
causes of death**





old data: in 2015 things have changed (yes?)

BMT for acquired SAA > 40 years of age

	2001-2010	2010-2015	
N=	327	427	
Age (med)	49 yy	53 yy	p<0.01
Alt donors	43%	64%	p<0.01
SC source	BM 41%	54%	p<0.01
FLU cont reg	42%	55%	p<0.01

Outcome of acquired SAA aged \geq 40 years : median 50 yy (40-77)





Age > 40 remains a significant risk factor for HLA id BMT, also in 2015

ATG+CyA (+EPAG?) should be first line therapy in acquired SAA > 40 years


The strong age effect persists >40 >50 >60 years

old data: in 2015 things have changed (yes?)

can we improve the conditioning for SAA in pts over 40 years?


SAA 2001-2010

HLA= SIB , Age > 40 years




SAA 2001-2010

HLA = SIB > 40 years




SAA 2001-2010; HLA id sibling transplants

The effect of age and the role of conditioning regimens



conditioning regimen for SIB transplants in acquired SAA > age of 40



FLUDARABINE 30 mg/m²/day x4




CYCLOPHOSPHAMIDE 30 mg/kg/day x4



ATG : 3.75 mg/kg/day (or CAMPATH 20 mg/day x5)

conditioning regimen for SIB transplants in acquired SAA > age of 40



FLUDARABINE 30 mg/m²/day x4



CYCLOPHOSPHAMIDE 30 mg/kg/day x4



ATG : 3.75 mg/kg/day



Total body irradiation 2 Gy for sensitized patients

Conditioning regimen SIB transplants

Young patients (<20 yy) CY200 +ATG

Older patients FLU CY ATG (± TBI 2)/ FCC

old data: in 2015 things have changed (yes?)

can we improve the conditioning for SAA in pts over 40 years?


and Unrelated Transplants?

Acquired SAA

No HLA = Sib

≤ 20 yy


UD BMT



Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT

© 2015 John Wiley & Sons Ltd

British Journal of Haematology, 2015, 171, 585–594



Acquired SAA

No HLA = Sib

≤ 20 yy

21-60 yy

ATG+CsA

no resp d+120

UD BMT



old data: in 2015 things have changed (yes?)

can we improve the conditioning for SAA in pts over 40 years?

and Unrelated Transplants?

best conditioning regimen ?



Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia

Judith C. Marsh, Vikas Gupta, ZiYi Lim, Aloysius Y. Ho, Robin M. Ireland, Janet Hayden, Victoria Potter, Mickey B. Koh, M. Serajul Islam, Nigel Russell, David I. Marks, Ghulam J. Mufti and Antonio Pagliuca

FCC (FLU CY CAMP 100)

UD n=29


SIB n=21

Age 35 (8-62)


DxTX 6mm (SIB) 10mm (UD)

BM(24) PB(14) GBM(7)


BM+PB (5)



FCC for aplastic anemia (AA)



conditioning regimen for UD transplants in acquired SAA: EBMT



FLUDARABINE 30 mg/m²/day x4



CYCLOPHOSPHAMIDE 30 mg/kg/day x4



ATG : 3.75 mg/kg/day

Ritux= 200 mg



Total body irradiation 2 Gy

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party

Andrea Bacigalupo,¹ Gerard Socie',² Edoardo Lanino,³ Arcangelo Prete,⁴ Franco Locatelli,⁵ Anna Locasciulli,⁶ Simone Cesaro,⁷ Avichai Shimoni,⁸ Judith Marsh,⁹ Mats Brune,¹⁰ Maria Teresa Van Lint,¹ Rosi Oneto,¹ and Jacob Passweg¹³ for the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAA WP-EBMT)

haematologica | 2010; 95(6)

Chronic GvHD

FCA	27%	ext 2%
FCA+TBI	50%	ext 8%




Figure 1. Actuarial survival of 52 SAA patients receiving FCA and 48 SAA patients receiving FCA + 2Gy TBI.

Conditioning regimen UD transplants

FLU CY CAMPTH (UK)

FLU CY ATG +TBI 2Gy (EBMT-USA-JAPAN)

old data: in 2015 things have changed (yes?)
can we improve the conditioning for SAA in pts over 40 years?
and Unrelated Transplants?
best conditioning regimen ?
how do UD compare with SIB transplants?

ORIGINAL ARTICLE

Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia

H Yagasaki¹, Y Takahashi¹, A Hama¹, K Kudo¹, N Nishio¹, H Muramatsu¹, M Tanaka¹, N Yoshida¹, K Matsumoto², N Watanabe³, K Kato², K Horibe³ and S Kojima¹

N=61 treated at
1 single Institution






Figure 1 Kaplan-Meier estimates of OS after MSD-BMT and URD-BMT, respectively (100% vs 93.8%) ($P = 0.252$).

Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group

Jing Chen,¹ Vincent Lee,² Cheng Juan
Luo,¹ Alan Kwok Shing Chiang,³
Suradej Hongeng,⁴ Poh Lin Tan,⁵
Ah Moy Tan,⁶ Kleebsabai Sanpokit,⁷
Chun Fu Li,⁸ Anselm Chi-wai Lee,⁹ Hsin
Chieh Chua⁵ and Yasuhiro Okamoto¹⁰

127 children
MSD n=50
MUD n=22
mMUD n=32
mmFAM n=20



ALLOGENEIC TRANSPLANTS FOR APLASTIC ANEMIA



Haematologica 2015; 100; 696



EBMT analysis 2014:

1448 patients

Adjusted effect of donor type (UD vs SIB) derived from the multivariate analysis
After adjusting for AGE, interval DxTx, use of ATG, use of BM/PB, and CMV status)



Low risk= age<20; ATG; BM; DxTx <180 dd
CMV D-/R-

High risk: Age >20; no ATG; PB; DxTx >180
CMV other than D-/R-

Fig. 1a Acute II-IV GvHD





Fig. 1b Chronic GvHD



Outcome of UD and SIB transplants

For SAA

**Currently almost superimposable
GvHD still more frequent in UD TX**

Acquired SAA

No HLA = Sib

≤ 20 yy

21-60 yy


ATG+CsA

no resp d+120

UD BMT


Alt Donor Tx

old data: in 2015 things have changed (yes?)
can we improve the conditioning for SAA in pts over 40 years?
and Unrelated Transplants?
best conditioning regimen ?
how do UD compare with SIB transplants?
stem cell source?



old data: in 2015 things have changed (yes?)
can we improve the conditioning for SAA in pts over 40 years?
and Unrelated Transplants?
best conditioning regimen ?
how do UD compare with SIB transplants?
stem cell source?
have results improved overall?

BONE MARROW TRANSPLANTATION



CONCLUSIONS

- # 40 years is still an age cut-off
- # there is a need for improvement in patients over 40: test prospectively 2 conditioning regimens
- # UD and SIB BMT now «almost» superimposable
- # BM remains the standard SC source
- # significant overall improvement of survival for BMT in SAA



GITMO Centers

LMC

EBMT WPSAA

C Dufour A Risiato

J Marsh J Passweg

H Schrezenmeier

G Socie' MT Van Lint

A Tichelli A Locasciulli

SMC

IBMDR
N Sacchi

Nursing Staff

Data Center
Rosi Oneto